New Drugs in Cancer Chemotherapy

  • Stephen K. Carter
  • Yoshi Sakurai
  • Hamoa Umezawa

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 76)

Table of contents

  1. Front Matter
    Pages I-XIV
  2. Introduction

  3. Anthracyclines

    1. R. H. Blum, M. B. Garnick, M. Israel, G. P. Panellos, I. C. Henderson, E. Frei III
      Pages 7-15
    2. R. L. Comis, S. J. Ginsberg, S. D. Reich, L. H. Baker, S. T. Crooke
      Pages 16-20
  4. Bleomycins

    1. S. Ikeda, H. Miyasato, H. Nakayama, K. Tajima, A. Sato
      Pages 41-60
    2. T. Miura, K. Katayama, T. Wada
      Pages 61-82
    3. S. T. Crooke, J. E. Strong, W. T. Bradner, J. Schurig, A. Schlein, A. W. Prestayko
      Pages 83-90
  5. Fluorinated Pyrimidines

  6. Nitrosoureas

    1. M. Ogawa, S. Fujimoto
      Pages 115-124
    2. K. D. Tew, M. E. Smulson, P. S. Schein
      Pages 130-140
  7. Other New Drugs

    1. F. M. Muggia, J. S. Penta, R. Catane, M. S. Jensen-Akula, L. M. Charles Jr.
      Pages 192-208
    2. K. Kimura, K. Yamada, Y. Uzuka, T. Maekawa, F. Takaku, M. Shimoyama et al.
      Pages 232-240
  8. Gastric Cancer

    1. P. S. Schein, J. S. Macdonald, P. V. Woolley, F. P. Smith, D. F. Hoth, M. Boiron et al.
      Pages 241-243
    2. M. Friedman, M. Ogawa, J. Hannigan, K. Kimura, Y. Sakurai, S. K. Carter
      Pages 249-256
  9. Oat Cell Lung Cancer

  10. Head and Neck Cancer

  11. Breast Cancer

  12. Back Matter
    Pages 337-338

About these proceedings


The Analog Potential in Cancer Chemotherapy in the United States and Japan S. K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that the therapeutic index of active structures can be improved so as to achieve superior clinical results.


Drugs Krebs Zytostatikum cancer cancer research chemotherapy drug drug development research

Editors and affiliations

  • Stephen K. Carter
    • 1
  • Yoshi Sakurai
    • 2
  • Hamoa Umezawa
    • 3
  1. 1.Northern California Cancer ProgramPalo AltoUSA
  2. 2.Cancer Chemotherapy CenterJapanese Foundation for Cancer ResearchToshima-ku, Tokyo 170Japan
  3. 3.Institute of Microbial ChemistryShinagawa-ku, Tokyo 141Japan

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1981
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-81567-6
  • Online ISBN 978-3-642-81565-2
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology